The Food and Drug Administration researchers said they reviewed 80 cases of Arava-associated peripheral neuropathy, a nerve problem involving numbness, tingling or pain in the hands or feet, and found the cases improved or recovered when the patients stopped taking the drug within 30 days of neuropathy onset. An FDA spokesperson said the study did not try to estimate the level of risk but added "it's probably low."

Full Story:
Reuters Health

Related Summaries